Spherison, an Italian healthtech startup developing neuroscience-based wellness solutions, has secured €500,000 in seed funding via a SAFE instrument. The round was led by Nobel laureate Federico Faggin, who had previously invested €150,000 in a pre-seed round, bringing total capitalization to €650,000.
The funding round also included backing from Pierpaolo Guerrini, Lando Santerini, and the investment firm 86k. The capital injection marks a significant milestone for the company as it pursues regulatory milestones and geographic expansion.
Technology and Market Position
Spherison has developed a proprietary “esanaurale” binaural-beat technology designed for neuro-wellness applications. The company has already established a presence across Italy and Switzerland, with approximately 100 installations currently in operation. The startup is simultaneously conducting clinical studies in collaboration with multiple universities and hospitals to validate the efficacy and safety of its approach.
The company’s focus on medical-device classification reflects its commitment to meeting rigorous regulatory standards rather than positioning itself purely as a consumer wellness product.
Regulatory and Commercial Strategy
The freshly raised capital will fund three primary objectives: obtaining Class I medical-device certification within Europe, preparing for submission to the U.S. Food and Drug Administration, and scaling commercial operations alongside technology licensing partnerships with global organizations.
This phased approach demonstrates the company’s intention to establish regulatory credibility in key markets before pursuing broader commercialization. The European certification represents an essential first step, followed by the more demanding FDA approval process required for market entry in the United States.
Alberto Baccari, a key figure supporting the company’s growth, highlighted the strategic importance of the funding. “When I learned about the esanaurale technology I understood it had to be known to the world, so my commitment is to accelerate capital raising and provide full technical support,” he stated.
Broader European Context
Spherison’s funding round reflects a broader trend within the European healthtech ecosystem, where startups are increasingly pursuing formal medical-device classifications rather than remaining in unregulated wellness categories. This regulatory-first approach carries higher upfront costs and longer timelines but positions companies for sustainable growth and partnership opportunities with established healthcare institutions.
The involvement of Federico Faggin, co-inventor of the microprocessor and a seasoned technology investor, signals confidence in both the company’s scientific foundation and its commercial potential. His participation underscores how established technology figures continue to identify emerging opportunities within European biotech and neuro-wellness sectors.
As European regulators place greater emphasis on substantiated health claims and product safety, startups like Spherison that proactively pursue certification may find themselves with competitive advantages in accessing institutional customers and insurance reimbursement pathways—critical factors for scaling beyond direct-to-consumer channels.